BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
Items per page:
1 - 1 of 1
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
Items per page:
1 - 1 of 1